comparemela.com
  1. Home
  2. Live Updates
  3. Nonobese Diabetic Mice - Breaking News

Latest Breaking News On - Nonobese diabetic mice - Page 1 : comparemela.com

COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model

/PRNewswire/ COUR Pharmaceuticals, a clinical stage biotechnology company developing novel immune-modifying nanoparticles (COUR NanoParticles or CNPs).

Northwestern universityUnited statesStephen millerJohnj puisisNon obese diabeticCell proteins prevent onsetNonobese diabetic miceParticle platformCour pharmaceutical development company inc

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.